Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.

Studied

This full-text narrative review and secondary analysis synthesized preclinical work, phase 2 data, and the SURPASS 1-5 trials of tirzepatide for type 2 diabetes.

Who / model

The six summarized clinical trials enrolled adults with type 2 diabetes and ran for 26 to 104 weeks, using placebo, semaglutide, dulaglutide, or basal insulin comparators.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Across SURPASS 1-5, tirzepatide reduced HbA1c by 1.69 to 2.58% and body weight by 5.4 to 11.7 kg. Nausea, vomiting, diarrhea, and constipation were the main adverse events.

Limits

This was a review, not one randomized trial. Cardiovascular analyses had few events, and the added contribution of GIP-receptor agonism remained uncertain.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary